UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-42437 Anteris Technologies Global Corp. (Exact name of Registrant as specified in its Charter) Delaware 99-1407174 (State or other ju ...

Operating Results (Unaudited) | | Three Months Ended | | | | | Year Ended | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | December 31, | | December 31, | | December 31, | | December 31, | | | (Millions of Dollars Unless Otherwise Stated) | 2025 | | 2024 | | 2025 | | 2024 | | | GAAP Net Income (Loss) Attributable to Stockholders | $ $ | (363) | | 82 $ | $ | (219) | | 998 | | Adjusted EBITDA | | 382 | | 164 | | 1,035 | | 770 | | Adjusted Free Cash Flow | | 292 | | 21 | | 524 | | 283 | | (a) ...

Exhibit 99.1 Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – February 26, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. Fourth Quarter 2025 and Recent Program Updates CLINICAL PROGRAMS Tividenofusp alfa (DNL310; ETV:IDS) for Hunter syndrome (mucopolysaccharidosis type II [MPS II]) Denali has es ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Payoneer Global Inc. (Exact name of registrant as specified in its charter) 001-40547 (Commission file number) Delaware 86-1778671 (St ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Payoneer Global Inc. (Exact name of registrant as specified in its charter) 001-40547 (Commission file number) Delaware 86-1778671 (St ...

COMPANY CONTACTS Briony Quinn Chief Financial Officer (240) 744-1196 Dori Kesten Capital Markets (617) 835-8366 DIAMONDROCK HOSPITALITY COMPANY REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS Comparable Total RevPAR Growth, Adjusted EBITDA, and Adjusted FFO Per Share Exceed High End of Guidance BETHESDA, Maryland, Thursday, February 26, 2026 – DiamondRock Hospitality Company (Nasdaq: DRH, the "Company"), a lodging real estate investment trust that owns a portfolio of 35 premium hotels and resorts in the U ...

Exhibit 99.1 Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance Business Highlights: Financial Results: Full Year 2026 Guidance: WILMINGTON, Del. – February 26, 2026 – Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the fourth quarter and full year 2025. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights. "Our ...

Financial Performance - FY 2025 revenue was $282.9 million, a decrease from $291.3 million in FY 2024[6] - Adjusted EBITDA for FY 2025 was $61.6 million, representing a 22% margin, down from $92.3 million and 32% margin in FY 2024[6] - Fourth quarter revenue was $80.0 million, compared to $85.5 million in Q4 2024[12] - GAAP net income for Q4 2025 was $6.7 million, down from $13.9 million in Q4 2024[12] - Gross profit for the year ended December 31, 2025, was $179,841,000, down from $190,229,000 in 2024, reflecting a decline of 5.5%[34] - Net loss for the year ended December 31, 2025, was $(14,462,000), compared to a net income of $12,504,000 in 2024[34] - Operating income for Q4 2025 was $8,524,000, down from $14,802,000 in Q4 2024, representing a decline of 42.2%[34] - Revenue for Q4 2025 was $80,046, a decrease from $85,502 in Q4 2024, with total revenue for 2025 at $282,926 compared to $291,256 in 2024[39] - Adjusted EBITDA for Q4 2025 was $27,818, down from $37,646 in Q4 2024, with a full year adjusted EBITDA of $61,640 for 2025 compared to $92,325 in 2024[39] - Non-GAAP net income for Q4 2025 was $14,440, compared to $21,443 in Q4 2024, with full year non-GAAP net income of $16,701 for 2025 versus $42,452 in 2024[39] Cash Flow and Assets - Free cash flow in FY 2025 was $46.2 million, an increase of 32% over FY 2024[6] - Total cash, cash equivalents, and marketable securities at the end of FY 2025 were $145.5 million, a 4% increase from FY 2024[6] - Cash and cash equivalents increased to $145,518,000 in 2025 from $100,452,000 in 2024, an increase of 44.8%[32] - Net cash provided by operating activities for Q4 2025 was $18,159, slightly up from $18,048 in Q4 2024, with total operating cash flow for 2025 at $81,059 compared to $73,425 in 2024[41] - Free cash flow for Q4 2025 was $6,852, down from $8,856 in Q4 2024, with total free cash flow for 2025 at $46,203 compared to $34,897 in 2024[41] Shareholder Actions - The company repurchased 4.1 million shares in 2025, representing 8.1% of fully diluted shares[1] - Total stock-based compensation for 2025 was $38,378, compared to $37,676 in 2024, indicating a slight increase in compensation expenses[39] Future Guidance - For Q1 2026, revenue is expected to be between $58 million and $60 million, with adjusted EBITDA guidance of $(0.5) million to $1.0 million[23] - The company expects to provide guidance for revenue and adjusted EBITDA for Q1 2026, indicating a focus on future growth[28] Market Performance - CTV revenue grew over 50% year-over-year in FY 2025, excluding political ad spend[17] - Net dollar-based retention rate for FY 2025 was 96%, indicating strong publisher satisfaction[6] Innovation and Strategy - The company continues to innovate in programmatic advertising, leveraging AI-driven optimization and privacy-focused solutions[29]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-K (Mark One) For the transition period from to Commission File No. 000-33043 OMNICELL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 94-3166458 (IRS Employer Identification No.) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Exhibit 99.1 • Revenue grew 10.2% to $931.8 million, approximately 10.9% on a constant currency basis • GAAP Net Income attributable to common shareholders was $141.6 million an increase of 25.7%, or $2.20 per diluted share • Adjusted EBITDA was $373.4 million an increase of 9.7% and Adjusted earnings per common share increased by 10.4% to $3.62 • $82.1 million returned to shareholders through share repurchases and dividends • Increased and extended share repurchase program EVERTEC REPORTS FOURTH QUARTER AN ...